Posted on

What Caught Our Attention in the Investment World? – Week of September 30-October 4, 2019

By Anil K. Ambastha and Kuldip K. Ambastha On September 26, Interactive Brokers (IBKR) announced a new IBKR Lite service effective from October that will feature unlimited, commission-free trades of U.S.-listed stocks and exchange traded funds (ETFs) along with no account minimum or inactivity fee. This news caused only a mild reaction on September 26 …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 30-October 4, 2019”

Posted on

What Caught Our Attention in the Investment World? – Week of September 9-13, 2019

By Kuldip K. Ambastha and Anil K. Ambastha Acadia Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company which has Nuplazid (aka: pimavanserin) in its product pipeline. Nuplazid has been used by individuals suffering from Parkinson’s disease-linked psychosis. Acadia has now analyzed Nuplazid in relation to individuals suffering from dementia-related psychosis. Currently, no approved drugs exist in …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 9-13, 2019”